It hasn't been a great 2021 so far for the CSL (ASX:CSL) share price

What's been impacting the biotech giant's shares this years?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has remained relatively flat when compared to the beginning of the year, up less than 3%. In comparison, the S&P/ASX 200 Index (ASX: XJO) is up almost 14% year to date.

During Wednesday's trading session, CSL shares continued to move largely sideways, sliding 0.69% to $292.28.

a doctor with stethoscope around neck sits as a computer with head in hand, looking despondent.

Image source: Getty Images

How is CSL comparing against the ASX 200?

On average, the ASX 200 has returned 6.50% per annum to shareholders over the last 5 years, and 5.78% per annum over its 10-year chart. The most significant gain was achieved in 2019 when the index grew 23.02%. On the other hand, the biggest fall came in 2011, when it lost 10.84%. Surprisingly, despite the pandemic-induced crash in 2020, that year did not deliver the biggest losses thanks to the ASX 200's sharp rebound.

Why is it worth looking at the 5-year and 10-year gains of the ASX 200? The reason is that, historically, CSL shares have outperformed the ASX 200 by a significant margin. Over the past 5 years, the company has delivered a 155% return. When looking at the last 10 years, the CSL share price has jumped by around 930% over the period.

What's been affecting the CSL share price lately?

CSL has been marred with plasma collection issues stemming from early 2020 when COVID-19 arrived on the world stage. Governments around the world enforced restrictions on passenger movements and closed down international borders in an effort to help curb the spiralling outbreak.

This was particularly bad news for CSL as it relies on the plasma from blood donors to make its life-saving medicines.

The company last provided an update in March advising that December 2020 plasma volumes were sitting at around 80% of December 2019 levels.

While current plasma levels are expected to eventually bounce back, no one can be certain exactly when this will occur. This uncertain environment has likely weighed on investor optimism, sending CSL shares in circles over the past 18 months.

The most recent broker note on CSL came from Macquarie yesterday. The broker cut its 12-month price target for CSL shares by 1.3% to $308.00. Based on the current CSL share price, this implies an upside of around 5% to investors.

CSL share price snapshot

Over the course of the past 12 months, CSL shares have taken investors on a rollercoaster ride, but are up just 5.08%. The company's shares are currently sitting just above the middle of their 52-week range of $242.00 to $320.42.

On valuation grounds, CSL is the third-largest company on the ASX with a market capitalisation of roughly $133 billion.

Motley Fool contributor Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A cool white-bearded man holds his hand up signalling you should halt.
Healthcare Shares

ASX 300 cannabis stock Incannex suspended ahead of 'material update'

The Incannex share price is frozen at 14 cents for now.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Guess which ASX All Ords stock is rocketing 27% on a new FDA approval

Rett Syndrome has finally got an approved treatment.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Buy these excellent ASX 200 healthcare shares: Goldman Sachs

Goldman has spoken very positively about these healthcare shares this week.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Guess which ASX biotech stock just rocketed 29% on big FDA news

The ASX healthcare share is attracting investor interest following FDA approval for its targeted cancer therapy compound.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares while they're under $300?

Can investors make a healthy return with this biotech?

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Mesoblast share price rockets 23% on FDA news

Mesoblast has received some good news for the US FDA this morning.

Read more »

A young woman wearing a blue blouse with white polkadots holds her phone up with an intrigued and happy look on her face as she reads some news.
Healthcare Shares

Owners of this ASX 200 share are soon going to receive a bigger dividend

Investors in this healthcare company are about to get a healthy cash boost.

Read more »

an older couple look happy as they sit at a laptop computer in their home.
Healthcare Shares

Hoping to collect the latest CSL dividend? Here's how

The next CSL dividend is fast approaching.

Read more »